BTS
CNCE

BB&T Securities’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

BB&T Securities’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$151K Buy
+25,740
New +$273K ﹤0.01% 1545

Other funds holding CNCE

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

BB&T Securities's CNCE Position: Q3 2019 in Review

BB&T Securities opened a new position in Concert Pharmaceuticals, Inc. (CNCE) in Q3 2019: 25,740 shares worth $151K. The stake represents ﹤0.01% of the portfolio and ranks #1545 among its holdings.

80 funds tracked by Wall St. Rank hold CNCE as of Q3 2019.

  • BB&T Securities held 25,740 shares of Concert Pharmaceuticals, Inc. worth $151K as of Q3 2019.
  • Concert Pharmaceuticals, Inc. was a new BB&T Securities position in Q3 2019.
  • Concert Pharmaceuticals, Inc. made up ﹤0.01% of BB&T Securities's portfolio in Q3 2019, its #1545 holding.
  • 80 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2019.

Based on BB&T Securities's 13F filing for Q3 2019, filed 30 Oct 2019.